Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission

Aarti Kinikar, MD, MRCP,* Nikhil Gupte, PhD,†‡ Jayalakshmi Bhat, MBBS, MPH,† Renu Bharadwaj, MD,⁎‡ Vandana Kulkarni, MD,⁎ Ramesh Bhosale, MD,⁎† Katherine N McIntire, MD,† Vidya Mave, MD, MPH,†‡ Nishi Suryavanshi, PhD,‡ Sandesh Patil, MBBS, DGO,† Robert Bollinger, MD, MPH,† and Amita Gupta, MD, MHS†§

Abstract: Syphilis is associated with increased human immunodeficiency virus acquisition and sexual transmission; we examined impact on human immunodeficiency virus mother-to-child transmission among mother-infant pairs enrolled in the India Six-Week Extended-Dose Nevirapine study. Maternal syphilis, diagnosed serologically using Venereal Disease Research Laboratory titer plus Treponema Pallidum Hemagglutination Assay, was associated with 2.5-fold greater risk.

Although curable with antibiotics, syphilis remains a public health challenge, particularly for exposed infants. Worldwide, the World Health Organization (WHO) estimates 36.4 million syphilis cases among adults of reproductive age (15–49 years); women account for 47% of the estimated 12 million new cases each year, including two million cases during pregnancy.¹ Maternal syphilis prevalence varies from 0.09% to 8.4% in different regions,² yet surveillance estimates fail to capture the severity largely due to underreporting and suboptimal treatment, particularly in developing countries.³,⁴

In 2012, an estimated 950,000 maternal syphilis infections resulted in 360,000 adverse outcomes.³ Prior WHO reports associate up to 80% of cases with poor infant outcomes, including mortality, neonatal infections, and low birth weight.² In high human immunodeficiency virus (HIV)/syphilis burden regions, such as Africa and Southeast Asia, syphilis may also place exposed pregnancies at increased risk of HIV mother-to-child transmission (MTCT).

Syphilis pathogenesis breaches the genital wall epithelium and may facilitate HIV virus entry into the bloodstream. Although studies have associated syphilis with increased HIV acquisition⁵ and sexual transmission,⁶ previous studies of perinatal HIV transmission have been limited by a variety of factors and have yielded mixed results.⁶–¹¹ Identifying maternal syphilis as an independent risk factor for HIV MTCT would suggest an important, modifiable target to be prioritized and addressed by prevention of MTCT (PMTCT) programs.

Currently, up to one third of antenatal care (ANC) attendees are not tested for syphilis,³,⁴ and many cases remain untreated or improperly treated. Access to treatment remains limited in many developing countries⁵ and in high burden countries, including India where only 70% of women receive ANC at different levels of the health system.¹² Evidence linking maternal syphilis and HIV MTCT could supplement existing outcome and surveillance data to secure increased financial and political support for integrated strategies for elimination of syphilis and HIV MTCT, including new point-of-care diagnostics.

MATERIALS AND METHODS

We conducted a secondary analysis of HIV-infected pregnant women and their infants who were enrolled in the India Six-Week Extended-Dose Nevirapine (SWEN) study, a National Institutes of Health (NIH)-funded phase III randomized controlled trial of extended infant nevirapine prophylaxis for prevention of breast milk HIV MTCT. The primary outcome was HIV-1 transmission at age 6 months; key secondary outcomes were to assess risk factors for HIV MTCT, including maternal co-infections, such as syphilis. Institutional review boards from Johns Hopkins University and the Byramjee Jeejeebhoy Government Medical College Ethics Committee approved the SWEN study methods, which are described elsewhere.¹³

Maternal syphilis was defined serologically; all mothers underwent screening at the first or second study visit using routine venereal disease research laboratory (VDRL) titer followed by confirmatory Treponema pallidum hemagglutination assay (TPHA). Mothers with reactive VDRL and TPHA assay tests were treated

From the *Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India; †Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD; ‡Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, Maharashtra, India; and §International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Acknowledgements: The authors thank the study participants and study staff for their immense contributions.

Sources of Support: This work was supported by the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases [R01AI095462]; the NIH Fogarty International Center Program of International Training Grants in Epidemiology Related to AIDS [D43TW00010-22]; the NIH Fogarty International Center Byramjee Jeejeebhoy Government Medical College (BJGMC) Johns Hopkins University HIV TB Program [D43TW009574]; The NIH BJMC HIV Clinical Trials Unit [U01AI069497 to AG, NG, VK, JS, VM, SP and RCB]; and the NIH Johns Hopkins Baltimore-Washington-India Clinical Trials Unit [UM1AI009465]. The study team was also supported by the Ujada Foundation, the Wyncote Foundation, and the Gilead Foundation for IndoUS research capacity building.

Conflict of interest: none declared.

Poster Presentation: American Academy of Pediatrics National Conference and Exhibition; San Diego, CA; October 11–14, 2014.

Correspondence: Aarti A Kinikar, MD, MRCP, Department of Pediatrics; BJMC; JaiPrakash Narayan Marg; Near Pune Station; Pune, Maharashtra 411001, India. E-mail: aarti.kinikar63@gmail.com.

Received for publication September 1, 2016, and accepted February 10, 2017.

DOI: 10.1097/OLQ.0000000000000622

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Sexually Transmitted Diseases Association.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
immediately with penicillin as per the national program. HIV-1 transmission was assessed at 48 hours post delivery and at each study visit (except weeks 3 and 5) using an in-house, externally validated HIV DNA polymerase chain reaction (PCR) assay developed at the National acquired immune deficiency syndrome (AIDS) Research Institute in Pune, India; a positive test was confirmed by HIV-1 RNA PCR at the next study visit. Due to concerns that prophylactic nevirapine might partially suppress viral load, 5000 copies/mL was used to define a positive HIV RNA PCR study (instead of 10,000 copies/mL) based on a modification of the Pediatric AIDS Clinical Trials Group definition for infant HIV diagnosis.1

Data were analyzed using STATA (version 12.0). Continuous variables are summarized using median and interquartile range (IQR) and compared using the Mann–Whitney rank-sum test. Maternal CD4 cell count and breastfeeding duration are categorized into clinically meaningful groups and compared using Fisher exact test. P values of 0.05 or less were deemed statistically significant. Univariable and multivariable Cox-proportional hazards models were used to assess the independent effect of maternal syphilis on time to HIV MTCT; follow-up was truncated at 6 months. Survival curves by syphilis coinfection status are nonintersecting hence satisfy Cox-regression assumptions. The analysis was adjusted for potential confounders that were statistically significant in univariate analysis as well as factors known to impact HIV transmission.1

RESULTS

A total of 658 HIV-infected mothers underwent syphilis screening and delivered live-born infants (Table 1). Median maternal CD4 count and HIV RNA load closest to delivery were 454 cells/mm3 (IQR, 312–648) and 3.73 log10 copies/mL (IQR, 2.91–4.52), respectively. A majority of women received ANC (IQR, 4.52–6.10; P = 0.02). P values of 0.05 or less were deemed statistically significant. Maternal-infant pairs were largely similar by maternal syphilis coinfection status (Table 1). Syphilis coinfected mothers were more likely to have a lower education level (P = 0.03) and less likely to have received ANC (P = 0.02).

A total of 67 (10%) infants were HIV-infected by 6 months. Maternal-infant characteristics by HIV transmission status have been previously described.13 HIV-1 transmission occurred in 7 (21%) of 34 syphilis-exposed infants compared to 60 (10%) of 624 unexposed infants; of these, 5 (15%) syphilis exposed infants and 21 (3%) unexposed infants were HIV-infected at birth. Kaplan-Meier estimated cumulative probability of HIV-1 transmission was higher in maternal syphilis HIV coinfection than HIV mono-infection (19.2%; 95% confidence interval [CI], 9.1%–37.8% vs 8.8%; 95% CI, 6.7%–11.4%) (Fig. 1). In multivariate analysis that adjusted for known maternal and infant risk and protective factors associated with HIV MTCT, maternal syphilis HIV coinfection was associated with 2.43-fold (95% CI, 1.004–5.89; P = 0.049) and 2.53-fold (95% CI, 1.05–6.10; P = 0.04) increased hazards of HIV-1 transmission in models that included and excluded maternal HAART antecedent to HIV transmission, respectively (Table 2).

DISCUSSION

Our secondary analysis of mother-infant pairs enrolled in the India SWEN study identifies maternal syphilis as an independent risk factor for HIV MTCT with approximately 2.5-fold increased risk. Maternal syphilis is potentially preventable and treatable using various cost-effective methods, including health education, screening, and early diagnosis and treatment of pregnant women and their partners.1415 Our findings provide new

| Characteristics | Overall | Maternal Syphilis Coinfection |
|-----------------|---------|-------------------------------|
| Maternal        |         |                               |
| Median age, y (IQR) | 23 (21–25) | 23 (21–25) | 22 (21–25) |
| Education > primary | 391 (59) | 14 (41) | 377 (60) |
| Hindu religion  | 510 (78) | 29 (85) | 481 (77) |
| Married         | 638 (97) | 34 (100) | 604 (97) |
| Housewife       | 530 (81) | 23 (68) | 507 (81) |
| Primigravida    | 230 (35) | 10 (29) | 220 (35) |
| ANC             | 427 (65) | 15 (44) | 412 (66) |
| Cesarean delivery | 128 (19) | 7 (21) | 121 (19) |
| Antenatal zidovudine | 428 (36) | 7 (21) | 231 (37) |
| Intrapartum nevirapine | 453 (69) | 21 (62) | 432 (69) |
| HAART during follow-up | 49 (7) | 1 (3) | 48 (8) |
| Median CD4 count, cells/mm3 (IQR) | 454 (312–648) | 510 (308–650) | 450 (312–648) |
| Median HIV RNA, log10 copies/mL (IQR) | 3.73 (2.91–4.52) | 3.73 (2.60–4.53) | 3.73 (2.91–4.51) |
| Tuberculosis     | 29 (4) | 4 (12) | 25 (4) |
| Infant           |         |                               |
| Median GA, weeks (IQR) | 38 (38–38) | 38 (37–38) | 38 (38–38) |
| Birth weight <2500 g | 261 (40) | 17 (50) | 244 (39) |
| Male sex         | 343 (52) | 16 (47) | 327 (52) |
| SWEN prophylaxis | 326 (50) | 17 (50) | 309 (50) |
| Breastfeeding duration >120 days | 274 (42) | 18 (53) | 256 (42) |

* Data presented as n(%) unless otherwise indicated.

GA, gestational age.
our observed
Investment in
373
were used to define ma-
include syphilis-mediated breaches
or less commonly evaluated factors, such as maternal-
Volume 44, Number 6, June 2017
and would decrease if the ef-
Syphilis-mediated immune activation
Thus, there are several biologically plau-
planations for the association o
perinatal transmission among syphilis-exposed infants. Possible ex-
logical abnormalities have been reported among placental and umbil-
additional to breaches in genital wall epithelium, common histopatho-
of maternal-fetal barriers and increased maternal infectiousness. In
Treponema pallidum
or the host immune response to the bacteria
Immune activation and inflammation may also increase
maternal infectiousness. This mechanism has been suggested to explain
syphilis-mediated immune activation
could increase HIV virus entry into the breast milk compartment, or
as with many other infections, could result in increased maternal
HIV viral load and decreased maternal CD4 count.
Our study has limitations. All factors that impact HIV MTCT
may not have been accounted for; we did not measure placental
malaria (prevalence was low in our population), chorioamnionitis, other STIs, or less commonly evaluated factors, such as maternal-
infant human leukocyte antigen status or presence of CCR5D32 mu-
tation. In addition, we did not examine the effect of syphilis stage or
nonTreponemal titer. None of the syphilis co-infected women in
our cohort had lesions on physical exam (data not shown); diagno-
sis was based entirely on seroreactivity during routine antenatal
screening. Early stage disease tends to be associated with greater
acute inflammation and may predispose women to increased risk of
vertical transmission.

Increased risk of HIV MTCT with maternal syphilis co-
infection emphasizes the need to expand syphilis screening by inte-
grating HIV and syphilis ANC services. Syphilis screening and treatment is a standard recommendation and is likely to be
cost-effective by WHO-defined thresholds in a wide range of set-
tings; current costs range from four to nineteen US dollars per
disability-adjusted life year averted and would decrease if the ef-
effect of syphilis on HIV MTCT were considered. Implementation,
however, has been patchy, which may be partially explained by the
increased resources required to implement both universal
HIV and syphilis testing in resource poor, high burden countries.
Notably, financial resources are growing for HIV PMTCT through
several donors, such as the Global Fund to fight AIDS, Tuberculosis
and Malaria, and will enable scale-up of interventions, including
antenatal HIV screening, particularly benefiting high prevalence
countries with low service coverage and high health care cost.
Further, a rapid dual immunoassay for syphilis and HIV recently
yielded 100% dual specificity and sensitivity of 93.8% for HIV
and 81.0% for syphilis in a NIH-funded field test. Investment in
such point-of-care diagnostics may yield improved outcomes be-
yond syphilis in resource-poor countries.

Our analysis expands the high burden of maternal syphilis
to include increased risk of HIV MTCT and is among the first
to assess the relationship between maternal syphilis and HIV
TABLE 2. Results of Cox Proportional Analysis to Identify Risk Factors Associated With Mother-to-Child HIV-1 Transmission in a Cohort of HIV-Infected Pregnant Women Screened for Maternal Syphilis in Pune, India (n = 658)

| Risk factor                  | HIV Transmission by 6 mo | Univariate Analysis | Multivariate Analysis* | Model I, aHRR (95% CI) | Model II, aHRR (95% CI) |
|------------------------------|--------------------------|---------------------|-------------------------|------------------------|-------------------------|
|                              | Yes, n (%) (N = 67)      | No, n (%) (N = 591) | P                       | HRR (95% CI)           | P                       |
| Maternal                     |                          |                     |                         |                       |                         |
| Median age, y (IQR)          | 24 (22–25)               | 23 (21–25)          | 0.10                    | 1.07 (0.99–1.14)       | 0.08                    |
| Education > primary          | 44 (51)                  | 357 (60)            | 0.15                    | 0.71 (0.43–0.99)       | 0.19                    |
| Hindu religion               | 55 (85)                  | 455 (77)            | 0.28                    | 1.52 (0.75–3.11)       | 0.25                    |
| Married                      | 66 (99)                  | 572 (97)            | 0.71                    | 1.78 (0.25–12.84)      | 0.57                    |
| Housewife                    | 47 (70)                  | 483 (82)            | 0.03                    | 0.46 (0.26–0.79)       | 0.005                   |
| Primigravida                 | 21 (31)                  | 209 (35)            | 0.59                    | 0.74 (0.42–1.30)       | 0.30                    |
| ANC                          | 30 (45)                  | 397 (67)            | <0.001                  | 0.50 (0.30–0.85)       | 0.10                    |
| Cesarean delivery            | 14 (21)                  | 114 (19)            | 0.75                    | 1.17 (0.59–2.32)       | 0.64                    |
| Antenatal AZT                | 13 (19)                  | 225 (38)            | 0.003                   | 0.46 (0.25–0.86)       | 0.01                    |
| Intrapartum NVP              | 40 (60)                  | 413 (70)            | 0.10                    | 0.82 (0.47–1.41)       | 0.47                    |
| HAART                        | 2 (3)                    | 47 (8)              | 0.22                    | 0.41 (0.10–1.67)       | 0.21                    |
| CD4 count < 350 cells/mm^3   | 33 (49)                  | 182 (31)            | 0.004                   | 2.23 (1.33–3.74)       | 0.003                   |
| Median HIV RNA, log_10 copies/mL (IQR) | 4.66 (3.99–5.10) | 3.59 (2.84–4.40) | <0.001                  | 2.54 (1.86–3.47)       | <0.001                  |
| Syphilis                     | 7 (10)                   | 27 (5)              | 0.07                    | 2.51 (1.08–5.84)       | 0.03                    |
| Tuberculosis                 | 10 (15)                  | 19 (3)              | <0.001                  | 4.77 (2.34–9.73)       | <0.001                  |
| Infant                       |                          |                     |                         |                       |                         |
| Median GA, wk (IQR)          | 38 (38–38)               | 38 (38–38)          | 0.37                    | 0.87 (0.72–1.06)       | 0.16                    |
| Birth weight < 2500 g        | 36 (54)                  | 225 (38)            | 0.02                    | 1.69 (1.01–2.85)       | 0.47                    |
| Male                         | 33 (49)                  | 310 (52)            | 0.70                    | 0.93 (0.56–1.57)       | 0.80                    |
| SWEN                         | 29 (43)                  | 297 (50)            | 0.30                    | 0.68 (0.40–1.16)       | 0.16                    |
| Breastfeeding duration > 120 d | 34 (51)                  | 240 (41)            | 0.15                    | 1.21 (0.72–2.04)       | 0.47                    |

* Multivariate analysis was adjusted for maternal CD4 count and viral load at delivery, married, housewife, mode of delivery, primigravida, Hindu religion, antenatal care, antenatal zidovudine, intrapartum nevirapine, maternal HAART, maternal tuberculosis, infant birth weight < 2500 g, breastfeeding duration > 120 days and infant SWEN prophylaxis; Model I includes maternal HAART initiation antecedent to infant HIV transmission; Model II excludes maternal HAART initiation antecedent to infant HIV transmission.

HRR, hazards rate ratio; aHRR, adjusted hazards rate ratio; AZT, zidovudine; NVP, nevirapine.
transmission in India, a country with the third highest global HIV burden. In addition to providing important data for Indian policy makers to ensure adequate resources for both syphilis and HIV testing among pregnant women, there is a broader need to: ensure access to ANC services; implement strategies for early syphilis detection and treatment at health care facilities; and identify and educate populations that do not access such facilities. Incorporating syphilis management into PMTCT programs would add little cost and have a major impact on child survival; continued efforts to develop and disseminate a rapid, easily interpreted dual HIV/syphilis point-of-care assay may improve outcomes.

REFERENCES

1. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. Geneva: WHO, 2012. Available at: http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf.

2. World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. Geneva: WHO, 2007. Available at: http://apps.who.int/iris/bitstream/10665/43782/1/9789241595858_eng.pdf.

3. WHO. Report on global sexually transmitted infection surveillance 2013. Geneva: WHO; 2014. Available at: http://apps.who.int/iris/bitstream/10665/112922/1/9789241507400_eng.pdf?ua=1.

4. Brunham RC, Embree JE. Sexually transmitted diseases: Current and future dimensions of the problem in the Third World. In: Germaine A, Holmes KK, Piot P, et al, eds. Reproductive tract infections: Global impact and priorities for women's reproductive health. New York: Plenum Press, 1992:35–58.

5. Kassutto S, Sax PE. HIV and syphilis coinfection: Trends and interactions. AIDS Clin Care 2003; 15:9–15.

6. Lee MJ, Hallmark RJ, Frenkel LM, et al. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. Int J Gynaecol Obstet 1998; 63:247–252.

7. Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS 2006; 20:1869–1877.

8. Yeganeh N, Watts HD, Camarca M, et al. Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study. Pediatr Infect Dis J 2015; 34:e52–e57.

9. St Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placent al factors. JAMA 1993; 269:2853–2859.

10. Van de Perre P, Simonon A, Mselati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med 1991; 325:593–598.

11. Cowan FM, Humphrey JH, Notzini R, et al. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: Results of a case control study. AIDS 2008; 22:193–201.

12. Ministry of Health and Family Welfare, Government of India. Annual report to the people on health. New Delhi: Ministry of Health and Family Welfare, 2011.

13. Bedri A, Gudetta B, Isehak A, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: An analysis of three randomised controlled trials. Lancet 2008; 372:300–313.

14. Ovwusu-Edusei K Jr, Tao G, Gift TL, et al. Cost-effectiveness of integrated routine offering of prenatal HIV and syphilis screening in China. Sex Transm Dis 2014; 41:103–110.

15. Kahn JG, Jiwani A, Gomez GB, et al. The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: A model. PLoS One 2014; 9:e87510.

16. Palacios R, Jiménez-Olarte F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:356–359.

17. Sheffield JS, Sánchez PJ, Wendel GD Jr, et al. Placental histopathology of congenital syphilis. Obstet Gynecol 2002; 100:126–133.

18. Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004; 18:2075–2079.

19. Ajisegi JG, van Eijk AM, Newman RD, et al. Maternal malaria and perinatal HIV transmission, western Kenya. Emerg Infect Dis 2004; 10:645–652.

20. Bhattar S, Bhailla P, Kawat D, et al. Correlation of CD4 T cell count and plasma viral load with reproductive tract infections/sexually transmitted infections in HIV infected females. J Clin Diagn Res 2014; 8:DC12–DC14.

21. Shivakoti R, Gupta A, Ray JC, et al. Soluble CD14: an independent biomarker for the risk of mother-to-child transmission of HIV in a setting of preexposure and postexposure antiretroviral prophylaxis. J Infect Dis 2015; Oct 6 pii: jiv479 [epub ahead of print].

22. Chi BH, Mudenda V, Levy J, et al. Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. Am J Obstet Gynecol 2006; 194:174–181.

23. World Health Organization. HIV/AIDS and other sexually transmitted infections. Geneva: WHO, 2015. Available at: http://www.who.int/hiv/topics/diagnoses/hiv.csv.

24. Wang AL, Qiao YP, Wang LH, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull World Health Organ 2015; 93:52–56.

25. Schmid G. Economic and programmatic aspects of congenital syphilis prevention. Bull World Health Organ 2004; 82:402–409.

26. Bristow CC, Leon SR, Huang E, et al. Field evaluation of a dual rapid immunodiagnostic test for HIV and Syphilis infection in Peru. Sex Transm Dis 2016; 43:57–60.